FDA Approves Adcetris for Refractory Hodgkin’s Disease and a Rare T-Cell Lymphoma

Late Friday afternoon, the FDA announced its approval, upon accelerated review, of a new drug, Adcetris (brentuximab) for patients with Hodgkin’s lymphoma that has relapsed after bone marrow transplant and for some patients with T-cell anaplastic large cell lymphoma (ALCL). This interests me for a lot of reasons, among them that I used to work in the field of lymphoma immunology […]

Posted in cancer treatment, Communication, Medical News, Oncology (cancer)Tagged , , , , , , , , , , Leave a Comment on FDA Approves Adcetris for Refractory Hodgkin’s Disease and a Rare T-Cell Lymphoma